Auf dieser Seite
ASMB Assembly Biosciences, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 13, 2026
$22,54
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$21,8052-Wochen-Tief
$39,7152-Wochen-Hoch
Marktkapitalisierung (MRQ)
$447M
P/E (TTM)
18.6
EPS (TTM)
$1.21
Umsatz (TTM)
$75M
Ihre Abzeichen
52W-Spanne
$22–$40
Analystenbewertung
BUY
Kursziel
$52
P/E
18.6
ROE
-0.03%
Nettogewinnmarge
-0.06%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
ASMB Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$22.54
Marktkapitalisierung (MRQ)
$447M
P/E (TTM)
18.6
EPS (TTM)
$1.21
Umsatz (TTM)
$75M
ROE (TTM)
-0.03%
52W-Spanne
$22–$40
ASMB Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 12. Februar 2024 | 1-for-12 | Umgekehrt |
| 14. Juli 2014 | 1-for-5 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$72M2016-12-31 → 2025-12-31
EPS$-0.552021-12-31 → 2025-12-31
Freier Cashflow$-41M2016-12-31 → 2025-12-31
Nettogewinnmarge-0.06%2018-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | ASMB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | 18.65-Jahres-Durchschnitt ≈-15.0 | ≈-15.0 | · | · | |
| P/S (TTM) | 6.05-Jahres-Durchschnitt ≈58.6 | ≈58.6 | 75.6 | Unterbewertet | |
| K/B (MRQ) | 1.55-Jahres-Durchschnitt ≈4.9 | ≈4.9 | 2.6 | Unterbewertet | |
| Kurs / FCF (TTM) | -11.65-Jahres-Durchschnitt ≈-7.2 | ≈-7.2 | · | · | |
| Kurs / Cashflow (TTM) | -11.65-Jahres-Durchschnitt ≈-7.3 | ≈-7.3 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 1.75-Jahres-Durchschnitt ≈4.9 | ≈4.9 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | ASMB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -11.8%5-Jahres-Durchschnitt ≈-800.0% | ≈-800.0% | -1011.2% | Spitzenklasse | |
| EBITDA-Marge (TTM) | -11.6%5-Jahres-Durchschnitt ≈-796.5% | ≈-796.5% | -1011.2% | Spitzenklasse | |
| Pretax Margin (Vorgewinnmarge) | -8.5%5-Jahres-Durchschnitt ≈-779.8% | ≈-779.8% | -70.7% | Spitzenklasse | |
| Nettogewinnmarge (TTM) | -0.06%5-Jahres-Durchschnitt ≈-770.1% | ≈-770.1% | -919.8% | Spitzenklasse | |
| ROA (TTM) | -0.02%5-Jahres-Durchschnitt ≈-40.9% | ≈-40.9% | -39.6% | Spitzenklasse | |
| ROE (TTM) | -0.03%5-Jahres-Durchschnitt ≈-91.1% | ≈-91.1% | -45.6% | Spitzenklasse | |
| ROIC | -5.9%5-Jahres-Durchschnitt ≈-98.3% | ≈-98.3% | -34.0% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | ASMB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 14.05-Jahres-Durchschnitt ≈5.3 | ≈5.3 | 10.3 | Starke Liquidität | |
| Quick Ratio | 1.25-Jahres-Durchschnitt ≈1.7 | ≈1.7 | 5.2 | Geringe Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | ASMB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 153.5%5-Jahres-Durchschnitt ≈119.9% | ≈119.9% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 65.8% | · | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | -1.8% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | ASMB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.45-Jahres-Durchschnitt ≈0.2 | ≈0.2 | 0.2 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 148.55-Jahres-Durchschnitt ≈374.4 | ≈374.4 | 6.8 | Spitzenklasse | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$990.5K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
88.2%
Nächster Bericht
Nov 09, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 13, 2026 | $-0.20 | $-0.66 | 69.7% |
| 31. März 2026 | Mai 6, 2026 | $-0.54 | $-0.58 | 7.1% |
| 31. Dezember 2025 | $2.48 | $-0.66 | 474.1% | |
| 30. September 2025 | $-0.72 | $-0.79 | 8.9% | |
| 30. Juni 2025 | $-1.33 | $-1.39 | 4.5% | |
| 31. März 2025 | $-1.17 | $-1.63 | 28.3% | |
| 31. Dezember 2024 | $-1.57 | $-2.08 | 24.5% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72M | $29M | $7M | $0 | $6M | $79M | $16M | $15M | $9M | $0 | |
| R&D Expense | $65M | $56M | $49M | $70M | $69M | $107M | $86M | $73M | $44M | $33M | |
| SG&A Expense | $20M | $18M | $23M | $24M | $29M | $37M | $33M | $35M | $17M | $12M | |
| Operating Expenses | $84M | $74M | $72M | $94M | $139M | $144M | $119M | $108M | $61M | · | |
| Operating Income | $-12M | $-45M | $-65M | $-94M | $-133M | $-65M | $-103M | $-93M | $-52M | $-45M | |
| Other Non-op | $6M | $6M | $3M | $1M | $302.0K | $3M | $4M | $3M | $368.0K | $399.0K | |
| Pretax Income | $-6M | $-40M | $-61M | $-93M | $-132M | $-62M | $-98M | $-90M | $-52M | $-45M | |
| Income Tax | $0 | $330.0K | $33.0K | $0 | $-3M | $0 | $-774.0K | $1M | $-9M | $-618.0K | |
| Net Income | $-6M | $-40M | $-61M | $-93M | $-130M | $-62M | $-98M | $-91M | $-43M | $-44M | |
| EPS (Basic) | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-3.00 | · | · | · | · | · | |
| EPS (Diluted) | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-3.00 | · | · | · | · | · | |
| Shares (Basic) | 11,210,934 | 6,004,560 | 4,577,371 | 4,034,105 | 43,280,383 | · | · | · | · | · | |
| Shares (Diluted) | 11,210,934 | 6,004,560 | 4,577,371 | 4,034,105 | 43,280,383 | · | · | · | · | · | |
| EBITDA | $-12M | $-45M | $-64M | $-94M | $-132M | $-64M | $-102M | $-93M | $-52M | $-45M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58M | $38M | $20M | $52M | $46M | $59M | $47M | $41M | $82M | $29M | |
| Short-term Investments | · | · | · | · | · | · | · | $177M | $38M | $24M | |
| Receivables | $974.0K | $0 | $43.0K | $944.0K | $336.0K | $1M | $3M | $2M | $2M | $0 | |
| Prepaid Expense | $5M | $3M | $3M | $4M | $7M | $7M | $5M | $2M | $898.0K | $611.2K | |
| Current Assets | $255M | $116M | $134M | $97M | $154M | $224M | $283M | $223M | $123M | $54M | |
| PP&E (Net) | $221.0K | $284.0K | $385.0K | $743.0K | $1M | $2M | $2M | $557.0K | $860.0K | $214.7K | |
| PP&E (Gross) | · | · | $595.0K | $2M | $2M | $3M | $3M | $1M | $1M | $409.3K | |
| Accum. Depreciation | · | · | $210.0K | $2M | $1M | $2M | $1M | $1M | $414.0K | $194.6K | |
| Goodwill | · | · | · | · | · | $13M | $13M | $13M | $13M | $13M | |
| Intangibles | · | · | · | · | · | · | · | · | $29M | $29M | |
| Other Non-current Assets | $312.0K | $312.0K | $312.0K | $889.0K | $2M | $6M | $2M | $3M | $340.0K | · | |
| Total Assets | $258M | $119M | $137M | $102M | $191M | $283M | $340M | $268M | $169M | $98M | |
| Accounts Payable | $1M | $585.0K | $461.0K | $2M | $3M | $5M | $2M | $4M | · | · | |
| Accrued Liabilities | $8M | $7M | $6M | $7M | $7M | $12M | $8M | $10M | $6M | $5M | |
| Current Liabilities | $49M | $48M | $39M | $16M | $16M | $24M | $24M | $18M | $13M | $7M | |
| Capital Leases | $2M | $3M | $1M | $101.0K | $3M | $7M | $9M | $0 | · | · | |
| Deferred Tax | · | · | · | · | · | $3M | $3M | $3M | · | · | |
| Total Liabilities | $51M | $86M | $96M | $19M | $22M | $43M | $67M | $57M | $56M | $18M | |
| Common Stock | $16.0K | $7.0K | $5.0K | $4.0K | $48.0K | $34.0K | $32.0K | $25.0K | $20.0K | $17.2K | |
| Paid-in Capital | · | · | · | · | · | · | · | $553M | $365M | $289M | |
| Retained Earnings | $-832M | $-826M | $-786M | $-725M | $-631M | $-502M | $-439M | $-342M | $-251M | $-208M | |
| AOCI | $-41.0K | $-211.0K | $-81.0K | $-803.0K | $-419.0K | $-270.0K | $-201.0K | $-347.0K | $-392.0K | $-600.8K | |
| Stockholders' Equity | $207M | $33M | $41M | $83M | $169M | $241M | $273M | $211M | $113M | $80M | |
| Liabilities + Equity | $258M | $119M | $137M | $102M | $191M | $283M | $340M | $268M | $169M | $98M | |
| Shares Outstanding | 15,855,329 | 7,457,240 | 5,482,752 | 4,074,552 | 48,120,437 | 34,026,680 | 32,558,307 | 25,495,425 | 20,137,974 | 17,246,754 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $129.0K | $129.0K | $450.0K | $498.0K | $466.0K | $691.0K | $494.0K | $643.0K | $219.0K | · | |
| Stock-based Comp | $5M | $3M | $5M | $7M | $5M | $22M | $21M | $28M | $9M | $5M | |
| Deferred Tax | · | $0 | $0 | $0 | $-3M | $0 | $-774.0K | $1M | $-9M | $-618.0K | |
| Restructuring | · | · | $0 | $1M | $2M | $4M | $2M | · | · | · | |
| Other Non-cash | $-40M | $-14M | $78M | $2M | $33M | $-23M | $-7M | · | · | · | |
| Operating Cash Flow | $-41M | $-51M | $23M | $-84M | $-93M | $-63M | $-84M | $-65M | $2M | $-35M | |
| CapEx | $66.0K | $28.0K | $255.0K | $102.0K | $3M | $470.0K | $2M | $340.0K | $865.0K | $147.0K | |
| Investing Cash Flow | $-113M | $40M | $-69M | $91M | $27M | $68M | $-50M | $-135M | $-16M | $36M | |
| Stock Issued | $2M | $2M | $5M | $325.0K | $53M | $5M | $135M | $155M | $65M | · | |
| Net Stock Activity | $2M | $2M | $5M | $325.0K | $53M | $5M | $135M | · | · | · | |
| Financing Cash Flow | $175M | $29M | $14M | $614.0K | $53M | $8M | $140M | $160M | $67M | $153.0K | |
| Net Change in Cash | $20M | $19M | $-33M | $7M | $-14M | $13M | $5M | $-41M | $53M | $1M | |
| Taxes Paid | · | $400.0K | $0 | · | · | · | · | · | · | · | |
| Free Cash Flow | $-41M | $-51M | $22M | $-85M | $-96M | $-63M | $-86M | $-65M | $995.5K | $-35M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -16.8% | -159.3% | -902.5% | · | -2121.7% | -81.9% | -643.4% | -626.4% | · | · | |
| Net Margin | -8.5% | -140.9% | -854.8% | · | -2076.3% | -78.6% | -611.6% | -613.0% | · | · | |
| Pretax Margin | -8.5% | -139.7% | -854.3% | · | -2116.8% | -78.6% | -616.5% | -605.6% | · | · | |
| EBITDA Margin | -16.6% | -158.8% | -896.2% | · | -2114.2% | -81.0% | -640.4% | -626.4% | · | · | |
| ROA | -3.2% | -31.4% | -51.3% | -63.6% | -54.8% | -20.0% | -32.1% | -41.5% | -32.0% | -38.2% | |
| ROE | -5.5% | -135.4% | -147.9% | -100.6% | -66.0% | -24.3% | -45.4% | -41.2% | -44.4% | -44.6% | |
| ROIC | -5.9% | -137.3% | -157.4% | -113.9% | -77.0% | · | -37.3% | -44.6% | -38.1% | -55.9% |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 2.4 | 3.4 | 6.0 | 9.6 | 9.2 | 11.6 | 12.0 | 9.1 | 7.5 | |
| Quick Ratio | 1.2 | 0.8 | 0.5 | 3.3 | 2.9 | 2.5 | 2.1 | 11.9 | 9.1 | 7.4 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.2 | 0.1 | · | 0.0 | 0.3 | 0.1 | 0.1 | · | · | |
| Receivables Turnover | 148.5 | 1326.5 | 14.5 | · | 8.0 | 34.4 | 5.5 | 6.3 | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $13.04 | $4.47 | $7.50 | $1.69 | $3.51 | $7.07 | $8.39 | $8.26 | $5.62 | $4.63 | |
| Revenue / Share | $6.45 | $4.75 | $1.56 | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-3.67 | $-8.51 | $4.97 | $-1.74 | · | · | · | · | · | · | |
| Cash / Share | $3.69 | $5.14 | $3.62 | $1.07 | $0.95 | $1.75 | $1.44 | $1.63 | $4.07 | $1.66 | |
| EPS (TTM) | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-3.00 | $-1.77 | $-3.60 | · | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 153.5% | 298.2% | · | · | -92.1% | · | · | · | · | · | |
| Revenue CAGR 3Y | · | 65.8% | -55.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -1.8% | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $72M | $29M | $7M | $0 | $6M | $79M | $16M | $15M | $9M | $0 | |
| Net Income TTM | $-6M | $-40M | $-61M | $-93M | $-130M | $-62M | $-98M | $-91M | $-43M | $-44M | |
| Market Cap | $539M | $118M | $54M | $763M | $1.35B | $2.47B | $7.99B | $6.92B | $10.93B | $2.51B | |
| P/E | -61.8 | -2.4 | -0.7 | -0.7 | -9.3 | -41.0 | -68.2 | · | · | · | |
| P/S | 7.5 | 4.1 | 7.5 | · | 215.1 | 31.2 | 500.8 | 467.5 | 1212.4 | · | |
| P/B | 2.6 | 3.5 | 1.3 | 9.2 | 8.0 | 10.3 | 29.3 | 32.9 | 96.7 | 31.5 | |
| P / Tangible Book | 2.6 | 3.5 | 1.3 | 9.2 | 8.0 | 10.8 | · | · | · | · | |
| P / Cash Flow | -13.1 | -2.3 | 2.4 | -9.0 | -14.4 | -39.2 | -95.1 | -106.5 | 5878.7 | -72.1 | |
| P / FCF | -13.1 | -2.3 | 2.4 | -9.0 | -13.9 | -38.9 | -93.4 | -106.0 | 10984.2 | -71.8 | |
| Earnings Yield | -1.6% | -42.4% | -136.0% | -148.0% | -10.7% | -2.4% | -1.5% | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13M | $8M | $42M | $11M | $10M | $9M | $7M | $7M | $9M | $6M | $7M | $0 | $0 | $0 | · | · | |
| R&D Expense | $15M | $15M | $17M | $17M | $16M | $15M | $14M | $14M | $16M | $12M | $11M | $11M | $13M | $15M | $17M | $18M | |
| SG&A Expense | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $5M | $9M | $4M | $5M | $5M | $6M | $5M | |
| Operating Expenses | $20M | $20M | $23M | $22M | $21M | $19M | $19M | $18M | $21M | $17M | $20M | $15M | $17M | $20M | $23M | $23M | |
| Operating Income | $-6M | $-11M | $20M | $-11M | $-11M | $-10M | $-12M | $-11M | $-12M | $-11M | $-13M | $-15M | $-17M | $-20M | $-23M | $-23M | |
| Other Non-op | $2M | $2M | $2M | $2M | $895.0K | $1M | $1M | $1M | $1M | $2M | $2M | $628.0K | $592.0K | $609.0K | $583.0K | $256.0K | |
| Pretax Income | · | · | $22M | $-9M | $-10M | · | $-10M | $-10M | $-11M | · | $-11M | $-14M | $-17M | · | · | · | |
| Income Tax | · | · | $0 | $0 | $0 | · | $-76.0K | $0 | $406.0K | · | $33.0K | $0 | $0 | · | · | · | |
| Net Income | $-4M | $-9M | $22M | $-9M | $-10M | $-9M | $-10M | $-10M | $-11M | $-9M | $-11M | $-14M | $-17M | $-19M | $-22M | $-23M | |
| EPS (Basic) | $-0.20 | $-0.54 | $2.67 | $-0.72 | $-1.33 | $-1.17 | $-1.54 | $-1.51 | $-1.98 | $-1.66 | $-1.75 | $-3.29 | $-3.88 | $-4.46 | $-21.61 | $-0.48 | |
| EPS (Diluted) | $-0.20 | $-0.54 | $2.67 | $-0.72 | $-1.33 | $-1.17 | $-1.54 | $-1.51 | $-1.98 | $-1.66 | $-1.75 | $-3.29 | $-3.88 | $-4.46 | $-21.61 | $-0.48 | |
| Shares (Basic) | 18,853,646 | 16,900,232 | · | 12,686,122 | 7,655,854 | 7,506,321 | · | 6,351,431 | 5,642,752 | 5,483,313 | · | 4,380,444 | 4,355,007 | 4,251,037 | · | 48,448,399 | |
| Shares (Diluted) | 18,853,646 | 16,900,232 | · | 12,686,122 | 7,655,854 | 7,506,321 | · | 6,351,431 | 5,642,752 | 5,483,313 | · | 4,380,444 | 4,355,007 | 4,251,037 | · | 48,448,399 | |
| EBITDA | $-6M | $-11M | · | $-11M | $-11M | $-10M | · | $-11M | $-12M | $-11M | · | $-15M | $-17M | $-19M | · | $-23M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $32M | $31M | $58M | $23M | $24M | $23M | $38M | $28M | $19M | $19M | $20M | $27M | $22M | $43M | $52M | $55M | |
| Receivables | $822.0K | $451.0K | $974.0K | $912.0K | · | · | $0 | $0 | $0 | $43.0K | $43.0K | $0 | $342.0K | $717.0K | $944.0K | $1M | |
| Prepaid Expense | $7M | $6M | $5M | $3M | $2M | $4M | $3M | $3M | $4M | $4M | $3M | $3M | $4M | $6M | $4M | $5M | |
| Current Assets | $328M | $233M | $255M | $237M | $77M | $96M | $116M | $98M | $113M | $117M | $134M | $50M | $64M | $80M | $97M | $115M | |
| PP&E (Net) | $315.0K | $214.0K | $221.0K | $229.0K | $219.0K | $251.0K | $284.0K | $316.0K | $349.0K | $367.0K | $385.0K | $561.0K | $541.0K | $619.0K | $743.0K | $867.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $2M | · | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $2M | · | |
| Other Non-current Assets | $312.0K | $312.0K | $312.0K | $312.0K | $312.0K | $312.0K | $312.0K | $312.0K | $312.0K | $312.0K | $312.0K | $552.0K | $332.0K | $334.0K | $889.0K | $2M | |
| Total Assets | $331M | $236M | $258M | $240M | $81M | $99M | $119M | $100M | $115M | $120M | $137M | $52M | $67M | $83M | $102M | $122M | |
| Accounts Payable | $1M | $1M | $1M | $2M | $743.0K | $875.0K | $585.0K | $1M | $801.0K | $727.0K | $461.0K | $758.0K | $904.0K | $1M | $2M | $2M | |
| Accrued Liabilities | $3M | $3M | $8M | $6M | $3M | $2M | $7M | $5M | $4M | $2M | $6M | $4M | $4M | $3M | $7M | $6M | |
| Current Liabilities | $23M | $35M | $49M | $53M | $47M | $47M | $48M | $42M | $41M | $39M | $39M | $7M | $9M | $10M | $16M | $15M | |
| Capital Leases | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $113.0K | $451.0K | $791.0K | $1M | $50.0K | $64.0K | $80.0K | $101.0K | $918.0K | |
| Total Liabilities | $25M | $37M | $51M | $57M | $63M | $72M | $86M | $74M | $81M | $87M | $96M | $10M | $12M | $13M | $19M | $19M | |
| Common Stock | $20.0K | $16.0K | $16.0K | $16.0K | $8.0K | $8.0K | $7.0K | $6.0K | $6.0K | $5.0K | $5.0K | $53.0K | $52.0K | $52.0K | $4.0K | $48.0K | |
| Retained Earnings | $-845M | $-841M | $-832M | $-854M | $-845M | $-835M | $-826M | $-816M | $-806M | $-795M | $-786M | $-775M | $-760M | $-743M | $-725M | $-702M | |
| AOCI | $-623.0K | $-368.0K | $-41.0K | $-90.0K | $-279.0K | $-253.0K | $-211.0K | $-156.0K | $-293.0K | $-239.0K | $-81.0K | $-275.0K | $-325.0K | $-513.0K | $-803.0K | $-999.0K | |
| Stockholders' Equity | $306M | $199M | $207M | $183M | $18M | $27M | $33M | $26M | $35M | $33M | $41M | $42M | $55M | $70M | $83M | $102M | |
| Liabilities + Equity | $331M | $236M | $258M | $240M | $81M | $99M | $119M | $100M | $115M | $120M | $137M | $52M | $67M | $83M | $102M | $122M | |
| Shares Outstanding | 19,850,342 | 15,892,353 | 15,855,329 | 15,816,987 | 7,672,249 | 7,618,885 | 7,457,240 | 6,354,414 | 6,345,561 | 5,482,752 | 5,482,752 | 52,614,194 | 52,450,731 | 52,015,268 | 4,074,552 | 48,481,194 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $20.0K | $26.0K | $32.0K | $32.0K | $32.0K | $33.0K | $32.0K | $33.0K | $32.0K | $32.0K | $84.0K | $116.0K | $126.0K | $124.0K | $124.0K | $134.0K | |
| Stock-based Comp | $2M | $1M | $1M | $2M | $834.0K | $712.0K | $751.0K | $797.0K | $833.0K | $739.0K | $959.0K | $1M | $1M | $2M | $2M | $2M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $-700.0K | $800.0K | |
| Other Non-cash | · | $-14M | · | · | · | $-15M | · | · | · | $-10M | · | · | · | $-6M | · | · | |
| Operating Cash Flow | $-15M | $-22M | $14M | $-15M | $-17M | $-23M | $-407.0K | $-15M | $-17M | $-18M | $74M | $-14M | $-14M | $-23M | $-19M | $-20M | |
| CapEx | $0 | $19.0K | $24.0K | $42.0K | $0 | $0 | $0 | $0 | $14.0K | $14.0K | $71.0K | $136.0K | $48.0K | $0 | $0 | $102.0K | |
| Investing Cash Flow | $-92M | $-5M | $21M | $-158M | $17M | $7M | $-7M | $24M | $5M | $17M | $-90M | $19M | $-8M | $10M | $17M | $31M | |
| Stock Issued | $0 | $0 | $0 | $0 | $0 | $2M | $2M | $0 | $0 | $0 | $0 | $0 | $54.0K | $4M | $325.0K | $0 | |
| Net Stock Activity | · | $0 | · | · | · | $2M | · | · | · | $0 | · | · | · | $4M | · | · | |
| Financing Cash Flow | $109M | $149.0K | $456.0K | $172M | $357.0K | $2M | $17M | $0 | $12M | $0 | $9M | $0 | $134.0K | $4M | $437.0K | $0 | |
| Net Change in Cash | $1M | $-27M | $36M | $-1M | $593.0K | $-15M | $10M | $9M | $459.0K | $-1M | $-7M | $5M | $-22M | $-9M | $-2M | $12M | |
| Free Cash Flow | · | $-22M | · | · | · | $-23M | · | · | · | $-18M | · | · | · | · | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -47.4% | -138.4% | · | -100.9% | -115.2% | -105.5% | · | -160.1% | -143.0% | -185.5% | · | · | · | · | · | · | |
| Net Margin | -28.8% | -110.5% | · | -85.2% | -105.9% | -93.6% | · | -140.4% | -130.7% | -156.9% | · | · | · | · | · | · | |
| Pretax Margin | · | · | · | -85.2% | -105.9% | · | · | -140.4% | -125.9% | · | · | · | · | · | · | · | |
| EBITDA Margin | -47.4% | -138.1% | · | -100.9% | -115.2% | -105.2% | · | -160.1% | -143.0% | -184.9% | · | · | · | · | · | · | |
| ROA | -1.9% | -5.4% | · | -5.4% | -10.4% | -8.1% | · | -12.7% | -12.3% | -8.9% | · | -16.7% | -16.1% | -15.4% | · | -12.5% | |
| ROE | -2.4% | -8.0% | · | -8.8% | -38.6% | -29.5% | · | -28.4% | -24.9% | -17.6% | · | -20.0% | -18.9% | -17.5% | · | -14.1% | |
| ROIC | · | · | · | -6.0% | -61.3% | · | · | -42.1% | -36.5% | · | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.0 | 6.6 | · | 4.4 | 1.6 | 2.0 | · | 2.4 | 2.7 | 3.0 | · | 7.0 | 7.3 | 8.0 | · | 7.4 | |
| Quick Ratio | 1.4 | 0.9 | · | 0.4 | 0.5 | 0.5 | · | 0.7 | 0.5 | 0.5 | · | 3.7 | 2.5 | 4.4 | · | 3.6 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | · | · | · | · | · | |
| Receivables Turnover | 32.5 | 33.3 | · | 23.7 | · | · | · | · | 49.9 | 15.2 | · | · | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $15.40 | $12.50 | · | $11.55 | $2.36 | $3.56 | · | $4.09 | $5.47 | $5.95 | · | $0.79 | $1.05 | $1.35 | · | $2.11 | |
| Revenue / Share | $0.71 | $0.49 | · | $0.85 | $1.26 | $1.25 | · | $1.08 | $1.51 | $1.05 | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-1.31 | · | · | · | $-3.12 | · | · | · | $-3.35 | · | · | · | $-0.46 | · | · | |
| Cash / Share | $1.63 | $1.96 | · | $1.42 | $3.13 | $3.07 | · | $4.48 | $3.03 | $3.42 | · | $0.51 | $0.41 | $0.84 | · | $1.13 | |
| EPS (TTM) | $1.21 | $0.08 | · | $-4.76 | $-5.55 | $-6.20 | · | $-6.90 | $-8.68 | $-10.58 | · | $-33.24 | $-30.43 | $-27.06 | · | $-2.84 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75M | $71M | · | $37M | $33M | $32M | · | $28M | $21M | $13M | · | · | · | · | · | · | |
| Net Income TTM | $-42.0K | $-6M | · | $-39M | $-39M | $-40M | · | $-41M | $-46M | $-51M | · | $-73M | $-81M | $-89M | · | $-131M | |
| Market Cap | $545M | $441M | · | $405M | $139M | $73M | · | $96M | $87M | $73M | · | $562M | $724M | $524M | · | $954M | |
| P/E | 22.7 | 346.9 | · | -5.4 | -3.3 | -1.5 | · | -2.2 | -1.6 | -1.3 | · | -0.3 | -0.5 | -0.4 | · | -6.9 | |
| P/S | 7.3 | 6.2 | · | 10.9 | 4.2 | 2.3 | · | 3.4 | 4.1 | 5.6 | · | · | · | · | · | · | |
| P/B | 1.8 | 2.2 | · | 2.2 | 7.7 | 2.7 | · | 3.7 | 2.5 | 2.2 | · | 13.5 | 13.2 | 7.5 | · | 9.3 | |
| P / Tangible Book | 1.8 | 2.2 | · | 2.2 | 7.7 | 2.7 | · | 3.7 | 2.5 | 2.2 | · | 13.5 | 13.2 | 7.5 | · | 9.3 | |
| P / Cash Flow | · | -20.0 | · | · | · | -3.1 | · | · | · | -4.0 | · | · | · | -22.4 | · | · | |
| Earnings Yield | 4.4% | 0.29% | · | -18.6% | -30.6% | -64.8% | · | -45.6% | -63.3% | -79.5% | · | -311.2% | -220.5% | -268.4% | · | -14.4% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $72M | $29M | $7M | $0 | $6M |
| Betriebsgewinnmarge % | -16.8% | -159.3% | -902.5% | · | -2121.7% |
| Nettoergebnis | $-6M | $-40M | $-61M | $-93M | $-130M |
| Verwässerte EPS | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-3.00 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 5.2 | 2.4 | 3.4 | 6.0 | 9.6 |
| Quick Ratio | 1.2 | 0.8 | 0.5 | 3.3 | 2.9 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-41M | $-51M | $22M | $-85M | $-96M |
Institutionelle Eigentümer (13F) 98 Einreicher · $534.7M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
98
Gehaltener Wert
$534.7M
Neue Positionen
36
Geschlossene Positionen
13
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 36 (+19 vs. Vorquartal) | 13 (+4 vs. Vorquartal) | 34 (+6 vs. Vorquartal) | 17 (+1 vs. Vorquartal) | +5.9M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| GILEAD SCIENCES, INC. | $136.770.406 | 4.977.089 | 25,58% | Aktien |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $44.094.133 | 1.604.590 | 8,25% | Aktien |
| Paradigm Biocapital Advisors LP | $42.696.995 | 1.553.748 | 7,99% | Aktien |
| Commodore Capital LP | $38.884.200 | 1.415.000 | 7,27% | Aktien |
| RA CAPITAL MANAGEMENT, L.P. | $28.040.867 | 1.020.410 | 5,24% | Aktien |
| JANUS HENDERSON GROUP PLC | $23.479.147 | 849.309 | 4,39% | Aktien |
| BlackRock, Inc. | $21.072.187 | 766.819 | 3,94% | Aktien |
| Parkman Healthcare Partners LLC | $19.818.054 | 721.181 | 3,71% | Aktien |
| VANGUARD GROUP INC | $19.484.260 | 572.898 | 3,64% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $15.359.726 | 558.942 | 2,87% | Aktien |
| Point72 Asset Management, L.P. | $12.657.096 | 460.593 | 2,37% | Aktien |
| Seven Fleet Capital Management LP | $11.902.879 | 433.147 | 2,23% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $8.211.216 | 298.807 | 1,54% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $7.707.832 | 280.424 | 1,44% | Aktien |
| Schonfeld Strategic Advisors LLC | $6.654.363 | 242.153 | 1,24% | Aktien |
| AMERIPRISE FINANCIAL INC | $6.320.400 | 230.000 | 1,18% | Aktien |
| DV EQUITIES, LLC | $6.221.884 | 226.415 | 1,16% | Aktien |
| Aberdeen Group plc | $5.689.652 | 207.047 | 1,06% | Aktien |
| Affinity Asset Advisors, LLC | $5.221.200 | 190.000 | 0,98% | Aktien |
| B Group, Inc. | $4.828.401 | 175.706 | 0,90% | Aktien |
| STATE STREET CORP | $4.724.664 | 171.931 | 0,88% | Aktien |
| STEMPOINT CAPITAL LP | $4.681.987 | 170.378 | 0,88% | Aktien |
| Squadron Capital Management LLC | $4.396.800 | 160.000 | 0,82% | Aktien |
| Woodline Partners LP | $4.143.434 | 150.780 | 0,77% | Aktien |
| Driehaus Capital Management LLC | $4.122.000 | 150.000 | 0,77% | Aktien |
| Ally Bridge Group (NY) LLC | $3.847.200 | 140.000 | 0,72% | Aktien |
| GOLDMAN SACHS GROUP INC | $3.787.651 | 137.833 | 0,71% | Aktien |
| NORTHERN TRUST CORP | $3.380.837 | 123.029 | 0,63% | Aktien |
| FRANKLIN RESOURCES INC | $3.110.736 | 113.200 | 0,58% | Aktien |
| CITADEL ADVISORS LLC | $2.635.524 | 95.907 | 0,49% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.504.884 | 91.153 | 0,47% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $2.032.696 | 73.970 | 0,38% | Aktien |
| HighVista Strategies LLC | $2.017.170 | 73.405 | 0,38% | Aktien |
| Qube Research & Technologies Ltd | $1.414.890 | 51.488 | 0,26% | Aktien |
| MONIMUS CAPITAL MANAGEMENT, LP | $1.307.498 | 47.580 | 0,24% | Aktien |
| Trexquant Investment LP | $1.254.764 | 45.661 | 0,23% | Aktien |
| JPMORGAN CHASE & CO | $1.250.540 | 46.385 | 0,23% | Aktien |
| MORGAN STANLEY | $1.242.618 | 45.219 | 0,23% | Aktien |
| XTX Topco Ltd | $1.179.387 | 42.918 | 0,22% | Aktien |
| UBS Group AG | $1.148.829 | 41.806 | 0,21% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $1.083.839 | 39.441 | 0,20% | Aktien |
| Squarepoint Ops LLC | $940.201 | 34.214 | 0,18% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $800.437 | 29.128 | 0,15% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $665.098 | 24.203 | 0,12% | Aktien |
| Bank of New York Mellon Corp | $659.933 | 24.015 | 0,12% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $653.062 | 23.765 | 0,12% | Aktien |
| Caption Management, LLC | $627.341 | 22.829 | 0,12% | Aktien |
| ADAR1 Capital Management, LLC | $561.884 | 20.447 | 0,11% | Aktien |
| Palumbo Wealth Management LLC | $545.891 | 19.865 | 0,10% | Aktien |
| CITADEL ADVISORS LLC | $508.380 | 18.500 | 0,10% | Kaufoption |
Aktivisten & 5%+-Eigentümer 3 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. ×5 Einreichungen | 27. Mai 2026 | 25,10% | Änderung | · | SEC |
| Alexander Schornstein ×3 Einreichungen | 24. Juni 2024 | · | Erste Einreichung | · | SEC |
| 31. Oktober 2023 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 34 Insider · 14 Führungskräfte · 16 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Jason A Okazaki | CEO and President | 29. März 2026 A | 163.354 | 0 | 0 | $0 |
| Samar Michael P. | Chief Financial Officer | 25. Juli 2022 S | 77.228 | 0 | 0 | $0 |
| Thomas Joseph Russo | CFO | 29. März 2021 A | 54.633 | 0 | 0 | $0 |
| Graham K Cooper | Chief Financial Officer and Chief Operating Officer | 29. März 2019 A | 117.500 | 0 | 0 | $0 |
| Jeanette M Bjorkquist | PFO and PAO | 17. Juni 2026 S | 14.560 | 0 | 3 | $-9.429 |
| Anuj Gaggar | Chief Medical Officer | 29. März 2026 A | 42.688 | 0 | 0 | $0 |
| Nicole S White | Chief Manufacturing Officer | 29. März 2026 A | 48.145 | 0 | 2 | $-5.257 |
| William E Delaney IV | Chief Scientific Officer | 29. März 2026 A | 60.330 | 0 | 0 | $0 |
| Luisa M Stamm | Chief Medical Officer | 29. März 2022 A | 40.315 | 0 | 0 | $0 |
| Jacqueline Sybil Papkoff | SVP-CSO Microbiome | 14. Dezember 2020 S | 37.364 | 0 | 0 | $0 |
| Richard James Colonno | EVP & CSO, Virology Ops | 27. März 2020 A | 137.009 | 0 | 0 | $0 |
| Uri A Lopatin | Chief Medical Officer | 29. März 2019 A | 627.361 | 0 | 0 | $0 |
| Thomas E Rollins | Chief Development Officer | 29. März 2018 A | 3.750 | 0 | 0 | $0 |
| Thomas Andrew Rowland | Chief Business Officer | 15. Januar 2012 A | · | 0 | 0 | $0 |
| Michael Houghton | Direktor | 4. Juni 2026 A | 3.202 | 0 | 0 | $0 |
| Lisa Johnson-Pratt | Direktor | 4. Juni 2026 A | · | 0 | 0 | $0 |
| John G Mchutchison | Direktor | 4. Juni 2026 A | 18.347 | 0 | 0 | $0 |
| Gina Consylman | Direktor | 4. Juni 2026 A | · | 0 | 0 | $0 |
| Susan Mahony | Direktor | 4. Juni 2026 A | · | 0 | 0 | $0 |
| Anthony E Altig | Direktor | 4. Juni 2026 A | 40.000 | 0 | 0 | $0 |
| William R Ringo | Direktor | 5. Juni 2025 A | 17.465 | 0 | 0 | $0 |
| Richard D Dimarchi | Direktor | 25. Mai 2022 A | · | 0 | 0 | $0 |
| Myron Z Holubiak | Direktor | 20. Mai 2021 A | · | 0 | 0 | $0 |
| Helen Kim | Direktor | 11. Juni 2020 A | · | 0 | 0 | $0 |
| Alan Lewis | Direktor | 11. Juni 2020 A | · | 0 | 0 | $0 |
| Derek A Small | Direktor | 2. Januar 2020 A | 828.791 | 0 | 0 | $0 |
| Mark Auerbach | Direktor | 17. Mai 2019 A | · | 0 | 0 | $0 |
| Russell H Ellison | Direktor | 10. Juli 2014 A | 21.600 | 0 | 0 | $0 |
| Joseph Felder | Direktor | 6. März 2013 A | · | 0 | 0 | $0 |
| Gilead Sciences, Inc. | 10%-Eigentümer | 26. Mai 2026 A | 4.977.089 | 0 | 0 | $0 |
| Alexander Schornstein | 10%-Eigentümer | 25. November 2024 P | 728.113 | 0 | 0 | $0 |
| EcoR1 Capital Fund Qualified, L.P. | 10%-Eigentümer | 17. April 2018 P | · | 0 | 0 | $0 |
| Adam Zlotnick | 10%-Eigentümer | 10. Juli 2014 A | · | 0 | 0 | $0 |
| David Jonathan Barrett | · | 29. März 2017 A | 19.396 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 11 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,73% | 13.537 NS | 31. Juli 2026 | N-PORT |
| IWC · iShares Trust | 0,07% | 33.477 SH | 11. September 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 8.569 SH | 19. August 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 56.627 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,01% | 248.962 SH | 11. September 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 10.542 SH | 29. September 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 133.234 SH | 19. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 413.284 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 885 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,00% | 25.072 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | · | 88.727 SH | 11. September 2026 | Täglich |
ASMB Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 10 Analysten
KAUF
Median-Ziel
$52.00
+130,7%
4 40,0%
Starker Kauf
5 50,0%
Kauf
1 10,0%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
5 Analysten · 2026-09-20Mittelwert-Ziel $52.00 +130,7%
← Unter allen Zielen
Aktueller Preis $22.54
Tief$43.00
Mittelwert$52.00
Hoch$62.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| ASMB | $539M | -61.8 | 153.5% | -8.5% | -5.5% | · |
| CAPR | $1.66B | -12.8 | -11.6% | · | -51.1% | · |
| PROK | · | · | 1075.0% | -7725.2% | 6.9% | · |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | · |
| RGNX | $733M | -3.8 | 104.5% | -113.8% | -122.5% | · |
| OVID | $212M | -4.0 | 1181.3% | -240.1% | -18.7% | · |
| DMAC | $428M | · | · | · | -78.7% | · |
| TECX | $391M | -5.2 | · | · | -27.7% | · |
| MYGN | $575M | -1.6 | -1.6% | -44.4% | -96.8% | 69.9% |
| RZLT | $501M | -6.9 | · | · | -67.8% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 13, 2026